Bausch Health Surges on 3Q Beats, Rosier FY Outlook

By Adriano Marchese

Bausch Health surged after profit topped expectations in the third quarter, fueled by sales growth for its flagship gastrointestinal drug, and the pharmaceutical maker upgraded its guidance.

Shares trading in Toronto rose 21% to 11.72 Canadian dollars ($8.37).

The Laval, Quebec-based company now expects full-year revenue of $10.98 billion to $11.18 billion, up from a previous guidance for $10.79 billion to $11.04 billion.

Adjusted earnings before interest, taxes, depreciation and amortization are now projected to come in between $4.32 billion and $4.42 billion, up from the previous expectation for $4.05 billion to $4.18 billion.

The upgrades come after the company reported better-than-expected results in its third quarter late Wednesday. Bausch reported at 10% rise in revenue to $2.94 billion, topping forecasts of $2.75 billion, according to analyst expectations.

Net income rose to $436 million, from $179 million a year earlier. On a per-share basis, that was a rise to $1.15 from 48 cents.

Adjusted earnings came to $1.77 a share, handily beating the $1.27 a share expected by analysts.

Bausch from strong demand for its Xifaxan drug, which was the primary contributor to growth for its Salix segment, which focuses on gastroenterology therapies and saw revenue rise by 16% to $831 million.

Solta, its aesthetic-focused segment, saw an 18% rise in revenue to $165 million.

International revenue rose 5% to $299 million.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

October 29, 2026 10:32 ET (14:32 GMT)